Parkinson's disease (PD) afflicts millions of people worldwide. There are numerous drugs
available for PD; however, levodopa remains the gold standard of pharmacotherapy to …

Introduction: Parkinson's disease (PD) is one of the most challenging neurodegenerative
disorders to treat as it manifests with a large variety of troublesome, and often disabling …

Idiopathic Parkinson's disease (PD) is the only neurodegenerative disorder for which highly
effective symptomatic therapy is available. Although levodopa continues to be the gold …

Motor symptoms are a core feature of Parkinson's disease (PD) and cause a significant
burden on patients' quality of life. Oral levodopa is still the most effective treatment, however …

Parkinson's disease (PD) is the second most common neurodegenerative disease. The
prevalence is increasing with age and averages approximately 0.3% in the entire …

Parkinson's disease (PD) is a neurodegenerative disorder associated with the loss of
dopaminergic neurons in the substantia nigra. The decline of dopamine leads to motor …

Parkinson's disease (PD) is a neurodegenerative disorder characterized by resting tremor,
rigidity, and bradykinesia. The pathological processes begin years/decades before the first …

Over the decades, pharmaceutical treatments, particularly dopaminergic (DAergic) drugs
have been considered as the main therapy against motor symptoms of Parkinson's disease …

Parkinson's disease, a clinical syndrome with 4 cardinal features (bradykinesia, resting
tremor, increased muscular rigidity and impaired postural balance), is mainly caused by the …

Since the introduction of levodopa therapy in the 60's, there has yet to be a more efficacious
drug identified for the symptomatic treatment of Parkinson's disease (PD). Perhaps more …